Levetiracetam

Generic Name
Levetiracetam
Brand Names
Elepsia, Keppra, Matever, Roweepra, Spritam, Levetiracetam Accord, Levetiracetam Teva, Levetiracetam Actavis, Levetiracetam ratiopharm, Levetiracetam Sun, Levetiracetam Actavis Group, Levetiracetam Hospira
Drug Type
Small Molecule
Chemical Formula
C8H14N2O2
CAS Number
102767-28-2
Unique Ingredient Identifier
44YRR34555
Background

Levetiracetam is a drug within the pyrrolidine class that is used to treat various types of seizures stemming from epileptic disorders. It was first approved for use in the United States in 1999 and is structurally and mechanistically unrelated to other anti-epileptic drugs (AEDs). Levetiracetam possesses a wide therapeutic index and little-to-no potential t...

Indication

Levetiracetam is indicated as an adjunctive therapy in the treatment of partial onset seizures in epileptic patients who are one month of age and older. Additionally, it is indicated as an adjunct in the treatment of myoclonic seizures in patients with juvenile myoclonic epilepsy who are 12 years of age and older, and in primary generalized tonic-clonic seiz...

Associated Conditions
Epilepsies, Generalized Tonic-Clonic Seizures, Partial-Onset Seizures, Myoclonic seizures
Associated Therapies
-
Clinical Trials
Related News

Levetiracetam in the Treatment of Neuroleptic-induced Tardive Dyskinesia

Phase 2
Completed
Conditions
Dyskinesia, Medication-induced
First Posted Date
2005-09-15
Last Posted Date
2013-12-06
Lead Sponsor
UCB Pharma
Target Recruit Count
70
Registration Number
NCT00175955

A Placebo-controlled Study of Levetiracetam In Children (1mo to 4yrs of Age) With Partial Onset Seizures.

Phase 3
Completed
Conditions
Epilepsy, Partial
Interventions
Other: Placebo
Drug: Levetiracetam
First Posted Date
2005-09-15
Last Posted Date
2020-10-01
Lead Sponsor
UCB Pharma
Target Recruit Count
116
Registration Number
NCT00175890

Levetiracetam Versus Standard Antiepileptic Drugs (Carbamazepine and Valproate) Used as Monotherapy in Patients With Newly Diagnosed Epilepsy

First Posted Date
2005-09-15
Last Posted Date
2015-03-17
Lead Sponsor
UCB Pharma
Target Recruit Count
1701
Registration Number
NCT00175903

Levetiracetam Treatment in Adult Subjects With Parkinson's Disease Experiencing Troublesome Dyskinesias

Phase 2
Completed
Conditions
Idiopathic Parkinson Disease
First Posted Date
2005-09-12
Last Posted Date
2013-12-06
Lead Sponsor
UCB Pharma
Target Recruit Count
30
Registration Number
NCT00160576

Study to Evaluate the Safety and Efficacy of Levetiracetam in Patients Suffering From Idiopathic Generalized Epilepsy With Primary Generalized Tonic-clonic Seizures

Phase 3
Completed
Conditions
Generalized Convulsive Epilepsy
First Posted Date
2005-09-12
Last Posted Date
2013-11-26
Lead Sponsor
UCB Pharma
Target Recruit Count
154
Registration Number
NCT00160550

A Study to Determine if Levetiracetam Will Assist Those Suffering From Chronic Idiopathic Axonal Polyneuropathy.

First Posted Date
2005-09-12
Last Posted Date
2008-01-11
Lead Sponsor
Vanderbilt University
Target Recruit Count
30
Registration Number
NCT00156689
Locations
🇺🇸

Vanderbilt University Medical Center, Nashville, Tennessee, United States

Open Label Safety and Efficacy Study of Levetiracetam in Korean Patients With Epilepsy

Phase 3
Completed
Conditions
Epilepsy, Partial
First Posted Date
2005-09-12
Last Posted Date
2013-11-26
Lead Sponsor
UCB Pharma
Target Recruit Count
100
Registration Number
NCT00160628

A 16 Week Study Evaluating Levetiracetam in the Treatment of Post Herpetic Neuralgia (PHN)

Phase 2
Completed
Conditions
Neuralgia, Postherpetic
First Posted Date
2005-09-12
Last Posted Date
2013-11-26
Lead Sponsor
UCB Pharma
Target Recruit Count
170
Registration Number
NCT00160511

Follow-up Study of L059 (Levetiracetam) in Epileptic Patients With Partial Onset Seizures by Open Label Method

Phase 3
Completed
Conditions
Epilepsy, Partial
Interventions
Drug: Levetiracetam
First Posted Date
2005-09-12
Last Posted Date
2019-06-10
Lead Sponsor
UCB Japan Co. Ltd.
Target Recruit Count
154
Registration Number
NCT00160615

Open Label Safety and Efficacy Study of Levetiracetam in Patients With Epilepsy

Phase 4
Completed
Conditions
Epilepsy, Partial
Interventions
Drug: Levetiracetam
First Posted Date
2005-09-12
Last Posted Date
2020-08-19
Lead Sponsor
UCB Pharma
Target Recruit Count
251
Registration Number
NCT00160654
Locations
🇸🇬

N01036 806, Singapore, Singapore

🇨🇳

N01036 818, Tainan, Taiwan

🇲🇾

N01036 813, Kuala Lumpur, Malaysia

and more 26 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy